Company Information

  

Address: 30721 RUSSELL RANCH ROAD
SUITE 140 
City: WESTLAKE VILLAGE 
State: CA 
Zip Code: 91362 
Telephone: 818-264-2300 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Immunotherapy is an emerging approach to treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. While some other cancer immunotherapies target only a single cancer antigen, our technology can elicit an immune response against several antigens. Our clinical stage cancer immunotherapy programs are also distinguished by the fact that they target cancer stem cells (CSCs), which are the primary drivers of tumor growth and disease recurrence. Our most advanced product candidate, ICT-107, recently began phase 3 testing in which we anticipate randomizing approximately 542 patients at approximately 120 clinical sites in the U.S., Canada and Europe.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-1.81NAN/E
06/2017-3.77NAN/E
03/2017-5.04NAN/E
12/2016-5.87NAN/E
09/2016-336.00NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.22Total Liab/Total Assets0.64
Net Inc/Total Assets-1.31Total Liab/Inv Cap0.79
Net Inc/Inv Cap-1.62Total Liab/Comm Equity0.11
Pretax Inc/Net SalesNAInterest Coverage Ratio-11.20
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio3.78
Inventory TurnoverNACurrent Ratio4.14
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr Assets0.09
Net Sales/PP&ENA  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.14 0.99 0.79 1.95
Operating Income -3.90 -11.34 -5.48 -7.32
Interest Exp 0.00 0.43 0.45 0.78
Pretax Income -4.45 -3.61 -5.82 -6.32
Other Income -0.55 8.16 0.11 1.77
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -4.45 -3.61 -5.82 -6.32

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 6.01 1.81 5.34 11.44
Receivables - Total NA NA NA NA
Inventories - Total 0.00 0.00 1.30 1.19
Total Current Assets 6.72 4.40 7.14 13.41
Net Property, Plant & Equipment 0.06 0.08 0.09 0.11
Total Assets 6.78 4.81 10.51 16.89
Liabilities        
Accounts Payable 7.30 7.72 2.16 3.24
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 7.30 7.72 2.16 3.24
Long-Term Debt NA NA NA NA
Total Liabilities 7.30 7.75 10.03 10.76
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -116.01 -105.66 -102.05 -96.22
Treasury Stock NA NA NA NA
Total Stockholders' Equity -0.52 -2.94 0.48 6.13
Total Liabilities and Stockholders' Equity 6.78 4.81 10.51 16.89

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -2.22 -3.45 -6.07 -3.74
Net Cash Provided by Investing Activities 0.00 0.00 0.00 0.00
Net Cash Provided by Financing Activities 6.41 -0.07 -0.03 -0.12

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-14.50--
12/20130.00-8.80--
12/20140.00-9.38--
12/20150.00-12.79--
12/20160.00-22.09-5.87
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17211,0524.42




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.